June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Potential Approach to Reverse Corneal Myofibroblast Formation
Author Affiliations & Notes
  • Xiaoqing Q Guo
    Ophthalmology, Harvard Medical School, Schepens Eye Research Institute/MEE, Boston, Massachusetts, United States
  • Sriniwas Sriram
    Ophthalmology, Harvard Medical School, Schepens Eye Research Institute/MEE, Boston, Massachusetts, United States
  • Jennifer A Tran
    Ophthalmology, Harvard Medical School, Schepens Eye Research Institute/MEE, Boston, Massachusetts, United States
  • Audrey E K Hutcheon
    Ophthalmology, Harvard Medical School, Schepens Eye Research Institute/MEE, Boston, Massachusetts, United States
  • James D Zieske
    Ophthalmology, Harvard Medical School, Schepens Eye Research Institute/MEE, Boston, Massachusetts, United States
  • Footnotes
    Commercial Relationships   Xiaoqing Guo, p38 MAP Kinase Inhibitors for Wound Healing--Schepens Eye Research Institute/MEE (P); Sriniwas Sriram, None; Jennifer Tran, None; Audrey Hutcheon, None; James Zieske, p38 MAP Kinase Inhibitors for Wound Healing--Schepens Eye Research Institute/MEE (P)
  • Footnotes
    Support  NIH Grant EY005665
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 136. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Xiaoqing Q Guo, Sriniwas Sriram, Jennifer A Tran, Audrey E K Hutcheon, James D Zieske; Potential Approach to Reverse Corneal Myofibroblast Formation. Invest. Ophthalmol. Vis. Sci. 2017;58(8):136.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : In previous studies, we found that transforming growth factor beta (TGFb) was involved in corneal wound healing. We also observed that blocking the TGFb/p38-signaling pathway in human corneal fibroblasts (HCF) prevented TGF-b1-stimulated HCFs from changing to a myofibroblastic phenotype. In the current study, we examined if p38 inhibitor (p38inh) could not only reduce, but also reverse levels of αSMA, a marker of myofibroblasts, in TGF-b1-stimulated HCFs, thus converting myofibroblasts back to their fibroblastic phenotype.

Methods : HCF were treated with EMEM ± 2ng/ml TGF-β1 (T1) for 3 days. After rinsing with PBS three times, the 3 day T1-treated cells were split into two groups: 1) regular medium (RM: EMEM+10%FBS), and 2) p38inh medium (RM+10μM SB202190, a p38 inhibitor) for an additional 3 days. Media was changed everyday, and cells were harvested on days 1, 2, and 3 (D1, D2, and D3, respectively) for aSMA analysis by western blot (WB) and qRT-PCR. HCF grown in EMEM only (HCF control) or EMEM + T1 (T1 control) served as controls.

Results : The WB results showed that αSMA protein levels in T1 control were significantly higher than HCF control (p<0.001). After splitting T1 cells into RM or p38inh, αSMA levels in both groups continued to increase at D1, compared to T1 control. On D2, the αSMA protein levels in the RM sample leveled out; however, in the p38inh sample, the αSMA levels decreased and were significantly lower than the D2 RM sample (p<0.05). By D3, αSMA protein levels in both medias decreased; however, the p38inh’s αSMA level continued to be lower than that in the RM sample, which returned to T1 control level. The qRT-PCR data showed a similar pattern as WB.

Conclusions : αSMA levels in both RM and p38inh samples abated with time; however, the presence of p38inh significantly accelerated this reverse. Therefore, blocking the p38 pathway may be a potential approach to reversing corneal myofibroblast formation after wounding.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×